Cargando…

Clinical factors associated with severe hypophosphataemia after kidney transplant

BACKGROUND: The mechanism by which hypophosphataemia develops following kidney transplantation remains debated, and limited research is available regarding risk factors. This study aimed to assess the association between recipient and donor variables, and the severity of post-transplantation hypopho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ralston, Maximilian R., Stevenson, Karen S., Mark, Patrick B., Geddes, Colin C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656060/ https://www.ncbi.nlm.nih.gov/pubmed/34886802 http://dx.doi.org/10.1186/s12882-021-02624-3

Ejemplares similares

Severe hypophosphataemia after intravenous iron administration
por: Anand, Gurpreet, et al.
Publicado: (2017)

Hypophosphataemia among Severely-malnourished Children: Case Series
por: Yoshimatsu, Shoji, et al.
Publicado: (2012)

Burosumab for X-linked hypophosphataemia
Publicado: (2021)

Incidence, severity and timing of hypophosphataemia in Glasgow Royal Infirmary ICU
por: Gilhooly, CJ, et al.
Publicado: (2009)

Hepatic osteodystrophy with hypophosphataemia and elevated fibroblast growth factor‐23
por: Ng, Nicholas Beng Hui, et al.
Publicado: (2022)

Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
por: Haffner, Dieter, et al.
Publicado: (2019)

Isolated hypophosphataemia as an early marker of primary hyperparathyroidism
por: Alexander, John, et al.
Publicado: (2021)

Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
por: Kamenicky, Peter, et al.
Publicado: (2023)

Symptomatic hypophosphataemia after intravenous iron therapy: an underrated adverse reaction
por: Ifie, Eseoghene, et al.
Publicado: (2019)

New Developments in the Treatment of X-Linked Hypophosphataemia: Implications for Clinical Management
por: Saraff, Vrinda, et al.
Publicado: (2020)

Life-threatening hypophosphataemia in a cirrhotic patient with jaundice
por: Moutzouri, Elisavet, et al.
Publicado: (2011)

Left Ventricular Hypertrophy in Patients with X-Linked Hypophosphataemia
por: Castellano-Martinez, Ana, et al.
Publicado: (2022)

Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials
por: Rosano, Giuseppe MC, et al.
Publicado: (2023)

Perioperative management of patients with severe hypophosphataemia secondary to oncogenic osteomalacia: Our experience and review of literature
por: Verma, Alka, et al.
Publicado: (2017)

Acute onset quadriparesis following oesophagectomy due to isolated hypophosphataemia
por: Naik, Vibhavari M, et al.
Publicado: (2019)

Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status
por: Fang, Wendy, et al.
Publicado: (2020)

Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review
por: Seefried, L., et al.
Publicado: (2020)

Treatment of hypophosphataemia in critically ill patients with a two day dosing regimen
por: Giles, LJ, et al.
Publicado: (2000)

Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy
por: Godaly, Gabriela, et al.
Publicado: (2016)

Oral health‐related quality of life in X‐linked hypophosphataemia and osteogenesis imperfecta
por: Gjørup, Hans, et al.
Publicado: (2020)

Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review
por: Kassianides, Xenophon, et al.
Publicado: (2021)

FGF23 is associated with early post-transplant hypophosphataemia and normalizes faster than iPTH in living donor renal transplant recipients: a longitudinal follow-up study
por: Prasad, Narayan, et al.
Publicado: (2016)

Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis
por: Schaefer, Benedikt, et al.
Publicado: (2020)

Ventricular bigeminy and trigeminy caused by hypophosphataemia during diabetic ketoacidosis treatment: a case report
por: Miszczuk, Konrad, et al.
Publicado: (2019)

Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies
por: Kubota, Takuo, et al.
Publicado: (2023)

Hungry bone syndrome and normalisation of renal phosphorus threshold after total parathyroidectomy for tertiary hyperparathyroidism in X-linked hypophosphataemia: a case report
por: Crowley, Rachel K, et al.
Publicado: (2014)

The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study
por: Padidela, Raja, et al.
Publicado: (2020)

XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)
por: Seefried, Lothar, et al.
Publicado: (2023)

A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose
por: Rosano, Giuseppe, et al.
Publicado: (2020)

Identification of a Novel Missense Mutation of the PHEX Gene in a Large Chinese Family with X-Linked Hypophosphataemia
por: Yang, Yanting, et al.
Publicado: (2022)

Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study
por: Kubota, Takuo, et al.
Publicado: (2020)

Exploring the Burden of X-Linked Hypophosphataemia: An Opportunistic Qualitative Study of Patient Statements Generated During a Technology Appraisal
por: Ferizović, Nermina, et al.
Publicado: (2019)

Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description
por: Brandi, Maria Luisa, et al.
Publicado: (2022)

Patient-reported outcomes measures of X-linked hypophosphataemia participants: findings from a prospective cohort study in the UK
por: Cole, Sophie, et al.
Publicado: (2023)

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
por: Briot, Karine, et al.
Publicado: (2021)

Characterization of Clinical and Genetic Risk Factors Associated with Dyslipidemia after Kidney Transplantation
por: Numakura, Kazuyuki, et al.
Publicado: (2015)

SARS-CoV-2 and Tacrolimus Blood Concentration in Kidney Transplant Recipients
por: McMinn, Jason, et al.
Publicado: (2021)

Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia
por: Harding, Brian, et al.
Publicado: (2009)

Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial
por: Zoller, Heinz, et al.
Publicado: (2023)

Correcting hypophosphataemia in a paediatric patient with Sanjad–Sakati syndrome through a single oral dose of potassium phosphate intravenous solution
por: Sabti, Mnaff A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_02b4743up7t320lca2lqop1d2o